The results of a recent study "Safety and Tumor Responses With Lambrolizumab (Anti PD-1) In Melanoma" indicate the drug Lambrolizumab can be effective in cancer treatment.
In the study the drug Lambrolizumab was administered to individuals living with advanced melanoma. The Lambrolizumab dosing contributed to a reduction in the size of the undesired (tumor) mass over a period of time.
Lambrolizumab is thought to disrupt the activity of the immune sign post protein PD-1 and this inhibits the ability of some cancerous processes to get around the bodies functioning immune system.
The drug Lambrolizumab is developed within Merck (MRK) and Company Incorporated. Merck is a stock traded on the (NYSE) New York Stock Exchange for approximately 48.50. Viewers are encouraged to watch and see how this drug is accepted in the market place.
You are cordially invited to download your free PATH ALONG app today
http://appsmakerstore.com/appim/j6kcdet8xvwk4s
Home Care Path www.homecarepath.com and the Wisconsin PATH ALONG model deliver an advanced supportive care service. Helping seniors in the home, with clinic visits, at the hospital, nursing home and assisted living facility. Helping seniors downsize with a move in to an adult child's home. 2013 rates are 20.00 per hour. Simply call 608-432-4286 to schedule an interview. We can be there when you are working. We accept long term care insurance. Services can be tax deductible. Help with resources and the transition from private payment to public funded programming. Valuing home and human life
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment